
## Marina V Nemtsova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3753202/publications.pdf Version: 2024-02-01



MADINA V NEMTSOVA

#	Article	IF	CITATIONS
1	Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis. Frontiers in Genetics, 2019, 10, 570.	1.1	109
2	Roles of E-cadherin and Noncoding RNAs in the Epithelial–mesenchymal Transition and Progression in Gastric Cancer. International Journal of Molecular Sciences, 2019, 20, 2870.	1.8	85
3	Identification of Novel Epigenetic Markers of Prostate Cancer by Notl-Microarray Analysis. Disease Markers, 2015, 2015, 1-13.	0.6	41
4	Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response. International Journal of Molecular Sciences, 2020, 21, 4911.	1.8	34
5	Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing. Scientific Reports, 2020, 10, 504.	1.6	34
6	The Effects of PPAR Stimulation on Cardiac Metabolic Pathways in Barth Syndrome Mice. Frontiers in Pharmacology, 2018, 9, 318.	1.6	31
7	Genome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectives. Epigenomics, 2019, 11, 605-617.	1.0	26
8	Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. Journal of Carcinogenesis, 2007, 6, 9.	2.5	21
9	Rapid and affordable genome-wide bisulfite DNA sequencing by Xmal-reduced representation bisulfite sequencing. Epigenomics, 2017, 9, 833-847.	1.0	13
10	Effect of the regulatory subunit of cAMP-dependent protein kinase on the genetic activity of eukaryotic cells. Molecular and Cellular Biochemistry, 1982, 49, 53-61.	1.4	12
11	Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer. Scientific Reports, 2021, 11, 2264.	1.6	12
12	Abnormal Hypermethylation of CpG Dinucleotides in Promoter Regions of Matrix Metalloproteinases Genes in Breast Cancer and its Relation to Epigenomic Subtypes and HER2 Overexpression. Biomedicines, 2020, 8, 116.	1.4	9
13	Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline MET Mutation in Russia. Frontiers in Oncology, 2019, 9, 1566.	1.3	7
14	Genes associated with testicular germ cell tumors and testicular dysgenesis in patients with testicular microlithiasis. Asian Journal of Andrology, 2018, 20, 593.	0.8	7
15	Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment. Journal of Personalized Medicine, 2020, 10, 205.	1.1	5
16	Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice. Current Genomics, 2017, 18, 408-415.	0.7	5
17	The role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer. Onkourologiya, 2019, 14, 124-138.	0.1	2
18	Basic characteristics and features of the molecular genetic test systems designed for non-invasive diagnostics and prognosis of prostate cancer and bladder cancer. Onkourologiya, 2020, 15, 18-29.	0.1	1

#	Article	IF	CITATIONS
19	Application Areas of Traditional Molecular Genetic Methods and NGS in relation to Hereditary Urological Cancer Diagnosis. Journal of Oncology, 2020, 2020, 1-12.	0.6	0
20	GENETIC ASPECTS OF TESTICULAR DYSGENESIS SYNDROME AND ASSOCIATED CONDITIONS. Onkourologiya, 2018, 14, 92-106.	0.1	0
21	Oncolytic Viruses As Immunotherapeutic Agents for the Treatment of Malignant Tumors. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 108-117.	0.2	0